Infliximab for treatment of pyoderma gangrenosum. 2015

K B Lankarani
Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz School of Medicine, Shiraz, Iran.

UI MeSH Term Description Entries
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017511 Pyoderma Gangrenosum An idiopathic, rapidly evolving, and severely debilitating disease occurring most commonly in association with chronic ulcerative colitis. It is characterized by the presence of boggy, purplish ulcers with undermined borders, appearing mostly on the legs. The majority of cases are in people between 40 and 60 years old. Its etiology is unknown.

Related Publications

K B Lankarani
April 2003, The British journal of dermatology,
K B Lankarani
March 2004, Clinical and experimental dermatology,
K B Lankarani
May 2013, Journal of Crohn's & colitis,
K B Lankarani
August 2002, European journal of gastroenterology & hepatology,
K B Lankarani
May 2007, The Australasian journal of dermatology,
K B Lankarani
September 2004, Digestive diseases and sciences,
K B Lankarani
January 2009, Acta dermato-venereologica,
K B Lankarani
June 2010, Journal of drugs in dermatology : JDD,
K B Lankarani
August 2003, The American journal of gastroenterology,
Copied contents to your clipboard!